Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics, Inc. - Common Stock
(NQ:
KYMR
)
40.66
+1.52 (+3.88%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,146,043
Open
38.66
Bid (Size)
32.50 (15)
Ask (Size)
53.55 (2)
Prev. Close
39.14
Today's Range
38.24 - 40.77
52wk Range
22.35 - 53.27
Shares Outstanding
55,307,775
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
The Latest Analyst Ratings For Kymera Therapeutics
November 01, 2024
Via
Benzinga
Preview: Kymera Therapeutics's Earnings
October 30, 2024
Via
Benzinga
Performance
YTD
+60.39%
+60.39%
1 Month
-6.55%
-6.55%
3 Month
-18.65%
-18.65%
6 Month
+29.28%
+29.28%
1 Year
+58.21%
+58.21%
More News
Read More
Insights Ahead: Kymera Therapeutics's Quarterly Earnings
October 30, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On Kymera Therapeutics
September 27, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
September 09, 2024
Via
Benzinga
Unveiling 6 Analyst Insights On Kymera Therapeutics
August 12, 2024
Via
Benzinga
Why Kymera Therapeutics Stock Is Soaring Today
July 09, 2024
Via
The Motley Fool
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
June 17, 2024
Via
Benzinga
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
May 24, 2024
Via
Benzinga
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
August 26, 2024
Via
Benzinga
Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
August 07, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
July 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
Via
Benzinga
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 09, 2024
Via
Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
July 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
July 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
Via
FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
May 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.